Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics is a biopharmaceutical company. Co. has built relevant capabilities in monoclonal antibody discovery and engineering, biologics manufacturing, and nonclinical and clinical development for thyroid eye disease (TED) and other undisclosed target indications in rare and autoimmune diseases. Co. is developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that are being developed for intravenous or subcutaneous administration to treat patients who suffer from TED. Co.'s primary program, VRDN-001, is a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor intravenously administered for the treatment for TED.
|
Free VRDN Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.86 out of 4) 75th percentile
(ranked higher than approx. 75% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|